Clinical trials: COVID19 ARDS
Respiratory Distress Syndrome, Hypoxemia
Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19
Vibroacoustic pulmonary therapy in patients with COVID19 is believed to have a positive effect on oxygen status and a decrease in the duration of respiratory failure
- Trial name
- NCT04435353
- Testing
- VibroLUNG
- Where
- 2 sites in Kazakhstan
- Volunteers
- 200 people
- Sponsor
- Astana Medical University
Dyspnea
Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU
Dyspnea is defined by a subjective sensation of respiratory discomfort, the intensity of which varies according to the terrain, the anamnesis and the cause.
- Trial name
- RECOVER (NCT04569266)
- Testing
- Specific exercise rehabilitation treatment, No specific exercise rehabilitation treatment
- Where
- 3 sites in France
- Volunteers
- 63 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Acute Respiratory Distress Syndrome, Covid19
Study of Descartes-30 in Acute Respiratory Distress Syndrome
Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19
- Trial name
- NCT04524962
- Testing
- Descartes 30
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cartesian Therapeutics
COVID-19, ARDS
Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial
This trial will determine the safety and estimate efficacy of targeted corticosteroids in mechanically ventilated patients with the hyper-inflammatory sub phenotype of ARDS due to coronavirus disease 2019 (COVID-19) by…
- Trial name
- NCT04360876
- Testing
- Dexamethasone injection
- Sponsor
- University of Colorado, Denver
COVID, Respiratory Distress Syndrome
BAttLe Against COVID-19 Using MesenchYmal Stromal Cells
The investigational medicinal product consists of expanded allogeneic mesenchymal stromal cells derived from adipose tissue and administered intravenously.
- Trial name
- NCT04348461
- Testing
- Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Sars-CoV2
Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic
SARS-CoV-2 induced by COVID 19, involved the hospitalization of 101,932 patients in France, including 4,007 in intensive care (source: Santé Publique France).
- Trial name
- COVID-PRONE (NCT04438941)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
COVID-19
Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)
The purpose of this study is to assess the efficacy and safety of prazosin to prevent cytokine storm syndrome and severe complications in hospitalized patients with Coronavirus disease 2019 (COVID-19).
- Trial name
- PREVENT (NCT04365257)
- Testing
- Prazosin, Standard of care
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
COVID-19
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
The primary purpose of Stage-I of this study is to evaluate the safety and tolerability of OP-101 in patients with severe COVID-19 and of Stage 2 of this study is to evaluate the efficacy of OP-101 in patients with severe…
- Trial name
- PRANA (NCT04458298)
- Testing
- OP-101
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ashvattha Therapeutics, Inc.
Virus Diseases, Pneumonia
Universal Anti-Viral Vaccine for Healthy Elderly Adults
This protocol tests the safety and efficacy of a novel universal vaccine concept called "allo-priming" which is designed to protect elderly adults from progression of any type of viral infection, including possible protection…
- Conditions
- Virus Diseases, Pneumonia, COVID-19 Respiratory Infection, RSV Pneumonia
- Trial name
- ALLOPRIME (NCT04441047)
- Testing
- AlloStim
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mirror Biologics, Inc.
COVID-19 Pneumonia
Nebulised Heparin in Patients With COVID-19 Pneumonia
While the pandemic continues to incite panic and the guideline recommendations regarding management of COVID continue to change, we have growing evidence that ARDS secondary to Covid-19 is associated with disseminated…
- Trial name
- NCT05255848
- Testing
- Unfractionated heparin
- Where
- Pakistan
- Volunteers
- 180 people
- Sponsor
- Lady Reading Hospital, Pakistan
COVID-19 Drug Treatment
Telmisartan for Treatment of COVID-19 Patients
In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications similar to those produced by the SARS coronavirus in the 2002-2003 epidemic.
- Trial name
- NCT04355936
- Testing
- Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.
- Where
- 2 sites in Argentina
- Volunteers
- 400 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS) is the main clinical presentation of SARS-CoV-2 (Covid-19) infected patients admitted in Intensive Care Unit (ICU).
- Trial name
- SONIC-19 (NCT04725084)
- Testing
- Use of High Flow Nasal Cannula alone, Use of Non-invasive Ventilation, Use of Continuous Positive Airway Pressure
- Where
- 4 sites in France
- Volunteers
- 355 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
COVID-19, Corona Virus Infection
Pre-exposure Prophylaxis for SARS-Coronavirus-2
Objective: To determine if pre-exposure prophylaxis with hydroxychloroquine is effective for the prevention of COVID-19 disease.
- Conditions
- COVID-19, Corona Virus Infection, ARDS, Acute Respiratory Distress Syndrome
- Trial name
- NCT04328467
- Testing
- Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 1,483 people
- Sponsor
- University of Minnesota
Corona Virus Infection, ARDS
Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches
In light of the rapidly emerging pandemic of SARS-CoV-2 infections, the global population and health care systems are facing unprecedented challenges through the combination of transmission and the potential for severe disease.
- Conditions
- Corona Virus Infection, ARDS, Coinfection
- Trial name
- MICRO-COV (NCT04410263)
- Testing
- Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine)
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- University of Zurich
Acute Respiratory Distress Syndrome, Covid19
Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19
Multi-centered, randomized, open label clinical trial to study the safety and effectivity of hydroxychloroquine + azithromycin to treat COVID-19 symptoms in primary care patients.
- Trial name
- AMBUCOV (NCT04954040)
- Testing
- Hydroxychloroquine Pill + Azithromycin Pill, SOC
- Where
- Spain
- Volunteers
- 132 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Covid19, SARS-CoV Infection
Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome
Acute treatment of COVID-ARDS with direct topical lung instilled T3 therapy for patients on mechanical ventilation.
- Conditions
- Covid19, SARS-CoV Infection, ARDS, ARDS, Human
- Trial name
- NCT04725110
- Testing
- Instilled T3
- Where
- United States
- Sponsor
- University of Minnesota
Acute Respiratory Distress Syndrome
Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)
The primary object of this clinical study is to investigate the efficacy and the safety of NOA-001 in patients with ARDS (ARDS caused by Non-COVID-19 or COVID-19).
- Trial name
- NCT04804943
- Testing
- NOA-001
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Toray Industries, Inc
COVID
Nebulised Rt-PA for ARDS Due to COVID-19
Some patients infected with COVID-19 develop a severe form of a lung disease called acute respiratory distress syndrome (ARDS). In these patients, the lungs become severely inflamed because of the virus.
- Trial name
- PACA (NCT04356833)
- Testing
- Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1, Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV, Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- University College, London
Acute Respiratory Distress Syndrome
Effectiveness of Convalescent Immune Plasma Therapy
The aim of the study is to evaluate the safety, improvement of clinical symptoms and laboratory parameters of convalescent immune plasma treatment in severe Covid-19 patients with ARDS.
- Trial name
- NCT04442958
- Testing
- Convalescent Immune Plasma
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Bagcilar Training and Research Hospital
Corona Virus Disease 19 (COVID-19), COVID
Rehabilitation for People With COVID-19 in ICU
COVID-19 DISEASE Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, severe acute respiratory syndrome from COVID-19, that was first recognized in Wuhan, China, in December…
- Conditions
- Corona Virus Disease 19 (COVID-19), COVID, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Critical Illness
- Trial name
- COVID_REHAB (NCT04381338)
- Testing
- Pulmonary and Motor Rehabilitation
- Where
- 2 sites in Italy
- Volunteers
- 96 people
- Sponsor
- University of Padova